Benzene Testing in Benzoyl Peroxide (BPO) Products

Benzene is one of the most strictly regulated impurities worldwide. Classified as a Class 1 carcinogen (ICH Q3C), its maximum allowable limit in pharmaceuticals and cosmetics is extremely low, only 2 ppm.

The Challenge

In formulations containing benzoyl peroxide (BPO), widely used in acne treatments, dermatology products, and topical pharmaceuticals, benzene formation poses a hidden risk. Not necessarily due to manufacturing but often due to how the product is analyzed.

Traditional methods, including Ph. Eur. 5.4 (Residual Solvents), rely on high-temperature headspace GC conditions that can artificially decompose BPO into benzene during analysis.

This leads to:

• False positive results
• Product recalls or rejections
• Regulatory non-compliance issues

Our Solution

Throughout 2024, LabSense's R&D team, in collaboration with scientific institutions and supported through the PK.1.1.06. national innovation program (Croatian Ministry of Economy and Sustainable Development)*, developed a low-temperature GC headspace method specifically designed to prevent BPO degradation.

By applying controlled conditions, we ensure that the analysis reflects the true benzene content in your finished product, not artificially generated levels.

Co-funded under the Croatian national recovery and resilience plan (2021–2026).